InVivo Therapeutics Appoints Christopher McNulty as Chief Financial Officer
March 29 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced the appointment of Christopher McNulty as Chief Financial
Officer (CFO), effective March 29, 2017. He will be taking over for
the interim CFO, Melanie Morel-Ferris, CPA, who will remain as the
company’s Senior Director, Finance and Controller.
Prior to being appointed Chief Financial Officer, Mr. McNulty
served at InVivo as Senior Vice President, Business Development and
Investor Relations, where he was responsible for evaluating all
partnerships and licensing opportunities. In addition to his
responsibilities in business development, Mr. McNulty played a key
role in the company’s financings, including a follow-on offering
and registered direct financing totaling an aggregate value of more
than $40 million. Prior to joining InVivo, Mr. McNulty served as
Senior Director, Business Development of Repligen Corporation. At
Repligen, he led all aspects of the company’s acquisition of
Novozymes Sweden, including financial modeling, diligence,
strategy, and negotiation. Previously, he served as Director,
Corporate Development at Seventh Sense Biosystems, where he was
responsible for corporate strategy, market evaluation, and business
development. Mr. McNulty received his B.S. and M.Eng. degrees in
electrical engineering and computer science from MIT, and his
M.B.A. from Harvard Business School.
Mark Perrin, CEO and Chairman of the Board, said, “I am very
pleased to have Chris as our new CFO. He has been instrumental in
our corporate financings and investor relations activities to date.
In addition, his background in strategic transactions and corporate
strategy will continue to make him a valuable asset in a range of
corporate activities.”
Perrin continued: “I also wish to acknowledge the excellent work
Melanie Morel-Ferris has done at InVivo since joining in mid-2016,
including her work as interim CFO. Melanie will remain as an
integral part of our finance team as the company’s Senior Director,
Finance and Controller.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials
and biotechnology company with a focus on treatment of spinal cord
injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD, Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, MD,
who then was at Boston Children’s Hospital and who now is
affiliated with Massachusetts General Hospital. In 2011 the company
earned the David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170329005549/en/
InVivo TherapeuticsHeather Hamel, 617-863-5530Investor
Relationsinvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024